According to clinical data, Roche’s new COVID-19 treatment Actemra/RoActemra lowered mortality risk in critically ill adult patients.
Results show support in favour of heterologous dosing which may help to advance vaccination programmes in poorer countries.
Former pharma CEO plundered millions from his own company, DOJ says fkansteiner Tue, 12/07/2021 – 11:16
Alvotech, battling AbbVie over its Humira biosim, raises $450M and tees up Nasdaq debut fkansteiner Tue, 12/07/2021 – […]
Civil society organisations have a critical role in a democracy, holding governments to account for their actions. This […]
A tribunal made an “error of law” when it restrained a GP accused of spreading misinformation about the […]
In mid-November our primary care network agreed to pause our delivery of booster vaccines, with the intention of […]
An important and urgent lesson from covid-19 is the need for properly resourced public services able to deal […]
Updated Date: Mon, 29 Nov 2021 00:00:00 EST
Updated Date: Mon, 29 Nov 2021 00:00:00 EST